Briacell Therapeutics Reports Promising Results from Clinical Trials of Bria-IMT™ Combination Regimen for Advanced Breast Cancer

Briacell Therapeutics Reports Promising Results from Clinical Trials of Bria-IMT™ Combination Regimen for Advanced Breast Cancer

Headline: Briacell Therapeutics Reports Promising Results from Clinical Trials of Bria-IMT™ Combination Regimen for Advanced Breast Cancer

Briacell Therapeutics Corp. (BCTX), a biotechnology company specializing in personalized cancer immunotherapy, has released its quarterly report showcasing promising results from its ongoing clinical trials. The company’s lead candidate, Bria-IMT™, in combination with Incyte’s retifanlimab, has demonstrated clinical benefit and potential survival benefits in heavily pre-treated advanced breast cancer patients.

The report highlights several significant developments for Briacell Therapeutics. Firstly, the company secured an exclusive license from the University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80), a biologic agent for cancer treatment. sCD80 has shown potential in animal models to stop tumor growth by restoring natural anti-tumor immunity. This novel technology holds promise for awakening and boosting the immune system to recognize and destroy tumor cells.

Additionally, Briacell Therapeutics signed an agreement with Caris Life Sciences®, a molecular science and technology company, to accelerate patient enrollment in its ongoing Phase I/II clinical trial for advanced metastatic breast cancer. Caris will utilize its expertise in molecular profiling to identify and enroll eligible patients, offering access to cutting-edge precision medicine in development.

Furthermore, the company added Mayo Clinic as a clinical site in its Phase I/II study for Bria-IMT™ in advanced breast cancer. The inclusion of Mayo Clinic strengthens the study’s reach and potential for success.

Most notably, Briacell Therapeutics announced positive initial efficacy data from its 2021-2022 cohort of 12 advanced breast cancer patients. The Bria-IMT™ regimen in combination with Incyte’s retifanlimab demonstrated evidence of disease control, tumor shrinkage, and potential survival benefit in the cohort. The treatment remained well-tolerated, with 70% of patients showing disease control or progression-free survival benefits compared to their previous therapies.

These promising results were further supported by data presented at the San Antonio Breast Cancer meeting, which reported tumor shrinkage, disease control, progression-free survival, and potential long-term survival benefits in advanced metastatic breast cancer patients treated with the Bria-IMT™ combination regimen. Many patients in the study reported a better quality of life and less pain compared to previous therapies.

Briacell’s off-the-shelf personalized immunotherapies, Bria-OTS+™ for advanced breast cancer and Bria-PROS™ for advanced prostate cancer, have also shown potential for strong immune responses in patients. The therapies activate naïve T cells and produce immune activating molecules, enhancing the immune system’s ability to target and destroy tumor cells.

In terms of patent issuance, Briacell Therapeutics received patents in the United States and Australia for its whole-cell cancer immunotherapy technology. The patents cover the composition of matter and method of use for the personalized off-the-shelf immunotherapies. These patents provide intellectual property protection until 2040 and validate the company’s innovative approach to cancer treatment.

Looking ahead, Briacell Therapeutics expects to initiate its Bria-OTS™ study under an Investigational New Drug Application (IND) in the second half of 2023. The company’s clinical sites are actively enrolling patients for its ongoing Phase II combination study across multiple locations in the United States.

Furthermore, Briacell Therapeutics received positive feedback from the FDA during its End of Phase II meeting for Bria-IMT™ in combination with a checkpoint inhibitor. The FDA’s agreement on study design and patient enrollment criteria paves the way for a pivotal clinical study that, if successful, could lead to the commercialization of the combination regimen for advanced metastatic breast cancer.

In summary, Briacell Therapeutics’ quarterly report showcases promising advancements in the development of personalized cancer immunotherapies. The positive results from clinical trials indicate the potential for improved outcomes and quality of life for patients with advanced breast cancer. With ongoing research and development, the company is at the forefront of innovative cancer treatments and has positioned itself for future success in the biotechnology industry.

Note that we may hold securities mentioned in this article. All data is based on recent SEC filings. Even though we have implemented various manual and automatic fact-checking and data acquisition processes, some incorrect information may have slipped through (false positive). Let us know if you find any inconsistencies!